{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T19:04:49Z","timestamp":1722884689927},"reference-count":21,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2011,12,8]],"date-time":"2011-12-08T00:00:00Z","timestamp":1323302400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cathet Cardio Intervent"],"published-print":{"date-parts":[[2012,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:styled-content>Objective<\/jats:styled-content>: We investigated the relation between duration of dual antiplatelet therapy (DAPT) and clinical outcomes up to 12 months after Genous\u2122 endothelial progenitor cell capturing R stent\u2122 placement in patients from the e\u2010HEALING registry. <jats:styled-content>Background<\/jats:styled-content>: Cessation of (DAPT) has been shown to be associated with the occurrence of stent thrombosis (ST). After Genous placement, 1 month of DAPT is recommended. <jats:styled-content>Methods<\/jats:styled-content>: Patients were analyzed according to continuation or discontinuation of DAPT at a 30\u2010day and 6\u2010month landmark, excluding patients with events before the landmark. Each landmark was a new baseline, and outcomes were followed up to 12 months after stenting. The main outcome for our current analysis was target vessel failure (TVF), defined as target vessel\u2010related cardiac death or myocardial infarction and target vessel revascularization. Secondary outcomes included ST. (Un)adjusted hazard ratios (HR) for TVF were calculated with Cox regression. <jats:styled-content>Results<\/jats:styled-content>: No difference was observed in the incidence of TVF [HR: 1.03; 95% confidence intervals (CI): 0.65\u20131.65, <jats:italic>P<\/jats:italic> = 0.89] in patients continuing DAPT (<jats:italic>n<\/jats:italic> = 4,249) at 30 days versus patients stopped (<jats:italic>n<\/jats:italic> = 309), and HR: 0.82 (95% CI: 0.55\u20131.23, <jats:italic>P<\/jats:italic> = 0.34) in patients continuing DAPT (<jats:italic>n<\/jats:italic> = 2,654) at 6 months versus patients stopped [<jats:italic>n<\/jats:italic> = 1,408] DAPT). Furthermore, no differences were observed in ST. Even after addition of identified independent predictors for TVF, adjusted TVF hazards were comparable. <jats:styled-content>Conclusions<\/jats:styled-content>: In a post\u2010hoc analysis of e\u2010HEALING, duration of DAPT was not associated with the occurrence of the outcomes TVF or ST. The Genous stent may be an attractive treatment especially in patients at increased risk for (temporary) cessation of DAPT or bleeding. \u00a9 2011 Wiley Periodicals, Inc.<\/jats:p>","DOI":"10.1002\/ccd.23156","type":"journal-article","created":{"date-parts":[[2011,5,3]],"date-time":"2011-05-03T15:31:06Z","timestamp":1304436666000},"page":"243-252","source":"Crossref","is-referenced-by-count":8,"title":["Duration of dual antiplatelet therapy and outcomes after coronary stenting with the genous\u2122 bio\u2010engineered R stent\u2122 in patients from the e\u2010healing registry"],"prefix":"10.1002","volume":"79","author":[{"given":"Peter","family":"Damman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margo","family":"Klomp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sigmund","family":"Silber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcel A.","family":"Beijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Expedito E.","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harry","family":"Suryapranata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaroslaw","family":"W\u00f3jcik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kui Hian","family":"Sim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan G.P.","family":"Tijssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robbert J.","family":"de Winter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the e\u2010Healing investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,12,8]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61444-5"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.826479"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.03.042"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.07.006"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.12.055"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi138"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.188208"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001266"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.01.048"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.4244\/EIJV3I3A64"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.4244\/EIJV6I7A141"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.685313"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.618066"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.686048"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehp275"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.297.2.joc60179"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.06.007"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.17.2126"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2006.02.039"},{"key":"e_1_2_7_21_2","unstructured":"KlompM. One\u2010year Outcomes of The TRIAS High\u2010Risk Trial. Presented at TCT conference 2010 Washington USA."},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2009.07.022"}],"container-title":["Catheterization and Cardiovascular Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fccd.23156","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ccd.23156","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T11:38:36Z","timestamp":1697456316000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ccd.23156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,8]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["10.1002\/ccd.23156"],"URL":"https:\/\/doi.org\/10.1002\/ccd.23156","archive":["Portico"],"relation":{},"ISSN":["1522-1946","1522-726X"],"issn-type":[{"type":"print","value":"1522-1946"},{"type":"electronic","value":"1522-726X"}],"subject":[],"published":{"date-parts":[[2011,12,8]]}}}